title: Improving memory and decreasing cognitive impairment in Tg-APPswe/PSEN1dE9 mice with Aβ3-10 repeat fragment plasmid by reducing Aβ deposition and inflammatory response.
abstract: The present study aimed to investigate the effects of Aβ3-10 repeat fragment plasmid for the treatment of Tg-APPswe/PSEN1dE9 (Tg) mice. The plasmid pcDNA3.1-(Aβ3-10)10-CpG was constructed and intramuscularly injected into 12-month-old Tg mice. Through the use of behavioral tests, anti-Aβ antibody and Aβ assays, cytokine assay, Aβ deposition, and astrocytes analysis results demonstrated that Aβ3-10 repeat fragment plasmid exhibited immunogenicity and reduced memory impairment in Tg mice via clearance of cerebral Aβ deposition, without significant side effects. Aβ3-10 repeat fragment plasmid immunization reduced Th1 cell-mediated immunity, secretion of interferon-γ, and stimulation to astrocytes. These data showed that the Aβ3-10 repeat fragment plasmid improved memory and decreased cognitive impairment in Tg mice by reducing Aβ deposition and inflammatory responses.
authors.affiliation: Department of Neurology, the First Affiliated Hospital of China Medical University, Shenyang, China. mayingwfd@yahoo.com.cn
authors.forename: Ying
authors.initials: Y
authors.lastname: Ma
authors.forename: Yu
authors.initials: Y
authors.lastname: Li
authors.forename: Li-Xia
authors.initials: LX
authors.lastname: Zong
authors.forename: Xiao-Na
authors.initials: XN
authors.lastname: Xing
authors.forename: Wei-Ge
authors.initials: WG
authors.lastname: Zhang
authors.forename: Yun-Peng
authors.initials: YP
authors.lastname: Cao
mesh_terms: D000544:Alzheimer Disease / Q000150:complications / Q000188:drug therapy / Q000235:genetics / Q000276:immunology; D016229:Amyloid beta-Peptides / Q000737:chemistry / Q000276:immunology / Q000378:metabolism / Q000627:therapeutic use* / Q000652:urine; D016564:Amyloid beta-Protein Precursor / Q000235:genetics; D000818:Animals; D000906:Antibodies / Q000097:blood; D001253:Astrocytes / Q000473:pathology; D001921:Brain / Q000378:metabolism; D003072:Cognition Disorders / Q000188:drug therapy* / Q000209:etiology / Q000652:urine; D016207:Cytokines / Q000378:metabolism; D004195:Disease Models, Animal; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D005904:Glial Fibrillary Acidic Protein / Q000378:metabolism; D007249:Inflammation / Q000188:drug therapy* / Q000209:etiology / Q000652:urine; D018782:Maze Learning / Q000502:physiology; D008569:Memory Disorders / Q000188:drug therapy* / Q000209:etiology / Q000652:urine; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D009154:Mutation / Q000235:genetics; D010446:Peptide Fragments / Q000378:metabolism*; D058225:Plaque, Amyloid / Q000378:metabolism / Q000473:pathology; D053764:Presenilin-1 / Q000235:genetics; D012091:Repetitive Sequences, Nucleic Acid / Q000276:immunology
chemical_list: D016229:Amyloid beta-Peptides; D016564:Amyloid beta-Protein Precursor; D000906:Antibodies; D016207:Cytokines; D005904:Glial Fibrillary Acidic Protein; C508853:PSEN1 protein, human; D010446:Peptide Fragments; D053764:Presenilin-1; C075222:amyloid beta-protein (1-42)